Watching ARCUTIS BIOTHERAPEUTICS, INC.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsExecutive ChangeItem 5.02 · 8-KLOW RiskPositive
ARCUTIS BIOTHERAPEUTICS, INC.
http://www.arcutis.com/Filed: Jul 15, 2026Westlake Village, CaliforniaCIK: 0001787306Health Care
AI Executive Summary
AI-powered analysis of 8-K filing content
Arcutis Biotherapeutics appointed Christopher Peetz as a new independent Class III director on July 15, 2026, expanding the board from nine to ten members. This board expansion strengthens governance oversight as the company continues to grow.
Key Takeaways
Christopher Peetz appointed as new Class III director, increasing board size from 9 to 10 members
Mr. Peetz confirmed as an independent director, enhancing board independence and governance compliance
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJul 15, 2026
Item5.02
CategoryExecutive Change
CIK0001787306
Accession #arqt-20260715
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.